DE69839443D1 - Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen - Google Patents

Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen

Info

Publication number
DE69839443D1
DE69839443D1 DE69839443T DE69839443T DE69839443D1 DE 69839443 D1 DE69839443 D1 DE 69839443D1 DE 69839443 T DE69839443 T DE 69839443T DE 69839443 T DE69839443 T DE 69839443T DE 69839443 D1 DE69839443 D1 DE 69839443D1
Authority
DE
Germany
Prior art keywords
antigen
cells
activated
pbls
loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839443T
Other languages
German (de)
English (en)
Inventor
Babita Agrawal
Mark J Krantz
Mark A Reddish
B Michael Longenecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cascadian Therapeutics Inc
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Application granted granted Critical
Publication of DE69839443D1 publication Critical patent/DE69839443D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69839443T 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen Expired - Lifetime DE69839443D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08
PCT/US1998/009288 WO1998050527A1 (en) 1997-05-08 1998-05-07 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells

Publications (1)

Publication Number Publication Date
DE69839443D1 true DE69839443D1 (de) 2008-06-19

Family

ID=21940709

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69839443T Expired - Lifetime DE69839443D1 (de) 1997-05-08 1998-05-07 Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
DE69842060T Expired - Lifetime DE69842060D1 (de) 1997-05-08 1998-05-07 Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69842060T Expired - Lifetime DE69842060D1 (de) 1997-05-08 1998-05-07 Verfahren zur Gewinnung aktivierter T-Zellen und mit Antigen-inkubierten Antigen-präsentierender Zellen

Country Status (10)

Country Link
US (1) US6600012B1 (enExample)
EP (3) EP0986636B1 (enExample)
JP (1) JP4480800B2 (enExample)
AT (2) ATE491465T1 (enExample)
AU (1) AU727863B2 (enExample)
CA (1) CA2289742C (enExample)
DE (2) DE69839443D1 (enExample)
DK (1) DK1634949T3 (enExample)
ES (1) ES2357960T3 (enExample)
WO (1) WO1998050527A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
DK1210430T3 (da) * 1999-09-08 2006-11-20 Transgene Sa MUC-1-afledte peptider
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
EP1499347A2 (en) 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
ES2375992T3 (es) * 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
AU2003258710A1 (en) * 2002-09-05 2004-03-29 Universitat Zu Koln Immunogenic muc1 glycopeptides
JP2006505554A (ja) * 2002-10-10 2006-02-16 デパートメント・オヴ・ヴェテランズ・アフェアズ 腫瘍特異的エピトープに向けられた、標識活性化リンパ球を使用した、腫瘍の検出、定位および染色
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
WO2005058937A2 (en) 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
WO2006050116A1 (en) * 2004-11-02 2006-05-11 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
DK1896051T3 (en) * 2005-06-28 2015-01-05 Oncothyreon Inc PROCESS FOR THE TREATMENT OF PATIENTS WITH A mucinous glycoprotein (MUC1) vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
AU2011226992B2 (en) 2010-05-10 2012-03-22 Ascend Biopharmaceuticals Pty Ltd Immunostimulatory and vaccine compositions
BR112013021779A2 (pt) 2011-02-24 2017-09-19 Oncothyreon Inc vacina de glicolipopeptídeo baseada em muc1 com adjuvante.
AU2013206896B2 (en) 2012-01-03 2017-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist CTL epitopes of the MUC1 tumor antigen
WO2014183823A1 (en) 2013-05-14 2014-11-20 Merck Patent Gmbh Method of treating lung cancer by vaccination with muc-1 lipopeptide
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
EP3986448A4 (en) * 2019-06-19 2023-07-12 Cue Biopharma, Inc. MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507984A (pt) 1994-06-13 1997-11-18 Unilever Nv Catalisador de alvejamento e de oxidação e composição alvejante
CA2192655A1 (en) * 1994-06-14 1995-12-21 Edgar G. Engleman Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
WO1996040066A1 (en) * 1995-06-07 1996-12-19 The Governors Of The University Of Alberta A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
ATE491465T1 (de) 2011-01-15
EP1634949A1 (en) 2006-03-15
ES2357960T3 (es) 2011-05-04
CA2289742A1 (en) 1998-11-12
DE69842060D1 (de) 2011-01-27
AU7371298A (en) 1998-11-27
EP2341072A3 (en) 2013-10-30
WO1998050527A1 (en) 1998-11-12
AU727863B2 (en) 2001-01-04
EP0986636A1 (en) 2000-03-22
JP2001525668A (ja) 2001-12-11
JP4480800B2 (ja) 2010-06-16
EP0986636B1 (en) 2008-05-07
ATE394474T1 (de) 2008-05-15
CA2289742C (en) 2013-07-16
EP1634949B1 (en) 2010-12-15
EP2341072A2 (en) 2011-07-06
US6600012B1 (en) 2003-07-29
DK1634949T3 (da) 2011-03-28

Similar Documents

Publication Publication Date Title
DE69839443D1 (de) Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
ATE506962T1 (de) Von survivin abgeleitete peptide und deren verwendung
DE69735851D1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
DE60120683D1 (de) Verfahren zur herstellung von membranvesikeln
EP1249490A3 (en) In vitro activation of cytotoxic T cells
TR200400149T2 (tr) Tümörlerin teşhisi ve tedavisi için mikroorganizmalar ve hücreler
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
IL219223B (en) Non-naturally occurring antigen-presenting cells (nnapc) derived from drosophila melanogaster cells for use in preparing a suspension of cd8+ cells and methods for their manufacture
DE3650184D1 (de) Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
ATE349198T1 (de) Zusammensetzung und verfahren zur krebs-antigen- immuntherapie
ES2167561T3 (es) Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
Slovin et al. Immunological approaches for the treatment of prostate cancer
ID29405A (id) Protein antigen tumor sart-3 yang baru dan peptida-peptida antigen tumornya
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
ATE276364T1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
RU2000122041A (ru) Способ лечения злокачественных опухолей головного мозга
UA36811A (uk) Спосіб визначення антитоксичної здатності замінників шкіри
MX9606317A (es) Metodos para la activacion de celulas t in vivo por celulas dentriticas impulsadas por antigenos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ONCOTHYREON, INC., SEATTLE, WASH., US

R079 Amendment of ipc main class

Ref document number: 986636

Country of ref document: EP

Free format text: PREVIOUS MAIN CLASS: C12N0005080000

Ipc: C12N0005078300